

Novugen Secured Patent Grant for Amlodipine and Valsartan Process Innovation | 14 August 2025



We are pleased to share that Novugen has been granted its fifth patent in Malaysia, this time for Amlodipine and Valsartan (AMVAL), recognizing an innovative manufacturing process. This significant milestone underwent a five-year examination process by MyIPO and was officially granted on 14 August 2025.

While Novugen AMVAL has been available in Malaysia since 2022, this newly granted patent protects a novel method of application that played a pivotal role in enabling the early launch of the product.

This achievement underscores our unwavering ambition to challenge the status quo and stands as a testament to the innovation and commitment of our team in driving meaningful impact for patients and shaping the future of pharmaceuticals accessibility.